stockrowLatest quarter
Vaxcyte reported adjusted earnings per share of −$1.97 for Q2 FY2026, missing the consensus estimate of −$1.47. Its diluted earnings per share were −$1.97, compared with −$1.22 a year earlier. The company’s free cash flow was −$236.8 million, compared with −$123.0 million in the prior-year quarter.
Vaxcyte is a clinical-stage biotechnology company developing vaccines against bacterial diseases and has no products approved for commercial sale. Its lead candidate, VAX-31, is being studied in adults and infants for pneumococcal disease, which can cause pneumonia and meningitis. The company is also developing VAX-24 for infants and VAX-XL for broader pneumococcal coverage. Vaxcyte uses its XpressCF platform to make proteins and antigens for vaccine candidates.
| Q2 FY2026 | Q2 FY2025 | Change | |
|---|---|---|---|
| Diluted EPS | −$1.97 | −$1.22 | — |
| Free cash flow | −$236.8 million | −$123.0 million | — |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | −$1.97 | −$1.47 | Missed by 34.0% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
No earnings call is available for the latest quarter, so management’s commentary cannot be reported.
Guidance
Management’s guidance for the latest quarter is not available, so its current outlook cannot be compared with its previous guidance. Vaxcyte has previously described plans for an infant program using an optimized formulation of either VAX-24 or VAX-31 after the VAX-31 infant results.